Neurogastrx

Neurogastrx is a privately held biopharmaceutical company based in Woburn, Massachusetts. The company employs 12 people and generates annual revenue of $1 million. Neurogastrx is dedicated to developing therapies for patients with serious gastrointestinal (GI) diseases where treatment options are limited. Neurogastrx focuses its efforts on developing treatments for erosive esophagitis (EE) and gastroparesis. Their targeted approach focuses on the gastroenterology community, leveraging the experience of their management team in developing and commercializing medicines within the GI field. Neurogastrx believes it has a significant opportunity to address the large unmet medical need for innovative GI treatments. Their research and development efforts aim to identify, develop, and efficiently bring to market solutions for GI diseases with limited innovation and/or treatment options. For more information about Neurogastrx, please visit their website at neurogastrx.com.